FDG PET in Prostate Cancer

PET Clinics

Volumn 4, Issue 2, 2009, Pages 155-161

  Jadvar, Hossein ^a  

^a NONE

Author keywords

Cancer; CT; FDG; PET; Prostate

Indexed keywords

CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOSE TRANSPORTER 1; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; GENE EXPRESSION; GENE FUNCTION; GLEASON SCORE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 68849091266     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.05.002     Document Type: Review

References (54)

1. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41 (2000) 661-681
2. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
3. Basu S., and Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 49 (2008) 17N-21N 37N
4. Hillner B.E., Siegel B.A., Liu D., et al. Impact of positron emission tomography/computed tomography and positron mission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26 (2008) 4229
5. Hillner B.E., Siegel B.A., Shields A.F., et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med 49 (2008) 1928-1935
6. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
7. Gambhir S.S. Molecular imaging of cancer: from molecules to humans. Introduction. J Nucl Med 49 Suppl 2 (2008) 1S-4S
8. Gillies R.J., Robey I., and Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 6 Suppl (2008) 24S-42S
9. Plathow C., and Weber W.A. Tumor cell metabolism imaging. J Nucl Med 49 6 Suppl (2008) 43S-63S
10. Medina R.A., and Owen G.I. Glucose transporters: expression, regulation and cancer. Biol Res 35 (2002) 9-26
11. Smith T.A. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 56 (1999) 285-292
12. Macheda M.L., Rogers S., and Bets J.D. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol 202 (2005) 654-662
13. Wilson J.E. Isoenzymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206 Pt 12 (2003) 2049-2057
14. Smith T.A. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57 (2000) 170-178
15. Pastorino J.G., and Hoek J.B. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 10 (2003) 1535-1551
16. Effert P., Beniers A.J., Tamimi Y., et al. Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res 24 5A (2004) 3057-3063
17. Stewardt G.D., Gray K., Pennington C.J., et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter 1 expression correlate with Gleason score. Oncol Rep 20 (2008) 1561-1567
18. Hara T., Bansal A., and DeGrado T.R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C]acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 33 (2006) 977-984
19. Palayoor S.T., Tofilon P.J., and Coleman C.N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 9 (2003) 3150-3157
20. Chandler J.D., Williams E.D., Slavin J.L., et al. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 97 (2003) 2035-2042
21. Jadvar H., Li X., Shahinian A., et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 4 (2005) 91-97
22. Oyama N., Kim J., Jones L.A., et al. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl Med Biol 29 (2002) 783-790
23. Agus D.B., Golde D.W., Squouros G., et al. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58 (1998) 3009-3014
24. Apolo A.B., Pandit-Taskar N., and Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 49 (2008) 2031-2041
25. Takahashi N., Inoue T., Lee J., et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 72 (2007) 226-233
26. Salminen E., Hogg A., Binns D., et al. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 41 5 (2002) 425-429
27. Pugachev A., Ruan S., Carlin S., et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 62 (2005) 545-553
28. Etchebehere E.C., Macapinlac H.A., Gonen M., et al. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18F-FDG PET. Q J Nucl Med 46 (2002) 122-130
29. Turlakow A., Larson S.M., Coakley F., et al. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med 45 (2001) 235-244
30. Jadvar H., Ye W., Groshen S., et al. [F-8]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med 22 (2008) 787-793
31. Effert P.J., Bares R., Handt S., et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155 (1996) 994-998
32. Hofer C., Laubenbacher C., Block T., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36 (1999) 31-35
33. Patel P., Cohade C., DeWeese T., et al. Evaluation of metabolic activity of prostate gland with PET-CT. J Nucl Med 43 5 Suppl (2002) 119P
34. von Mallek D., Backhaus B., Muller S.C., et al. Technical limits of PET/CT with 18FDG in prostate cancer. Aktuelle Urol 37 (2006) 218-221
35. Liu I.J., Zafar M.B., Lai Y.H., et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001) 108-111
36. Kao P.F., Chou Y.H., and lai C.W. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med 33 (2008) 308-310
37. Oyama N., Akino H., Suzuki Y., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29 (1999) 623-629
38. Kanamaru H., Oyama N., Akino H., et al. Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 46 (2000) 851-853
39. Shreve P.D., Grossman H.B., Gross M.D., et al. Metastatic prostate cancer: initial findings of PET with FDG. Radiology 199 (1996) 751-756
40. Morris N.J., Akhurst T., Osman I., et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59 (2002) 913-918
41. Yeh S.D., Imbriaco M., Larson S.M., et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23 (1996) 693-697
42. Jadvar H., Pinski J., and Conti P. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 10 5 (2003) 1485-1488
43. Jadvar H, Pinski J, Quinn D, et al. Concordance among FDG PET, CT and bone scan in men with metastatic prostate cancer. Proceedings of SNM 55th Annual Meeting, New Orleans (LA): 2008. p. 373P.
44. Chang C.H., Wu H.C., Tsai J.J., et al. Detecting metastatic pelvic lymph nodes by (18)f-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 70 4 (2003) 311-315
45. Schoder H., Herrmann K., Gonen M., et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11 (2005) 4761-4769
46. Sanz G., Robles J.E., Gimenez M., et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84 (1999) 1028-1031
47. Sung J., Espiritu J.I., Segall G.M., et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 92 (2003) 24-27
48. Seltzer M.A., Barbaric Z., Belldegrun A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162 (1999) 1322-1328
49. Haberkorn U., Bellemann M.E., Altmann A., et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 38 (1997) 1215-1221
50. Oyama N., Akino H., Suzuki Y., et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 22 (2001) 963-969
51. Zhang Y., Saylor M., Wen S., et al. Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol Imaging Biol 8 (2006) 300-308
52. Morris M.J., Akhurst T., Larson S.M., et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11 (2005) 3210-3216
53. Oyama N., Akino H., Suzuki Y., et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 4 (2002) 99-104
54. Jadvar H. [F-18]-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET-CT) in metastatic prostate cancer. USC Norris Comprehensive Cancer Center. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00282906. Accessed June 17, 2009.